Cargando…

Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?

Pulmonary arterial hypertension (PAH) is a progressive disease that despite advances in therapy is associated with a 7-year survival of approximately 50%. Several risk factors are associated with developing PAH, include methamphetamine use, scleroderma, human immunodeficiency virus, portal hypertens...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alamri, Ayedh K., Ma, Christy L., Ryan, John J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Leading Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074340/ https://www.ncbi.nlm.nih.gov/pubmed/37017914 http://dx.doi.org/10.1007/s40265-023-01862-z

Ejemplares similares

Novel Pulmonary Delivery of Drugs for the Management of Atrial Fibrillation
por: Islam, Nazrul, et al.
Publicado: (2022)

Are anticoagulants still indicated in pulmonary arterial hypertension?
por: Olschewski, Horst, et al.
Publicado: (2018)

Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19
por: Franco, Veronica, et al.
Publicado: (2020)

Chronic Pulmonary Aspergillosis—Where Are We? and Where Are We Going?
por: Hayes, Gemma E., et al.
Publicado: (2016)

Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?
por: Harari, Sergio, et al.
Publicado: (2015)

Early intervention: should we conduct therapeutic trials for mild pulmonary hypertension before onset of symptoms?
por: Huston, Jessica H., et al.
Publicado: (2019)

Cholangiocytes and the environment in primary sclerosing cholangitis: where is the link?
por: O’Hara, Steven P, et al.
Publicado: (2017)

Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?
por: Turnbull, Samantha, et al.
Publicado: (2015)

Utilizing proteomics to understand and define hypertension: where are we and where do we go?
por: Delles, Christian, et al.
Publicado: (2018)

Resistant Hypertension: Where are We Now and Where Do We Go from Here?
por: Pathan, Mansur K, et al.
Publicado: (2020)

Endolysosome and Autolysosome Dysfunction in Alzheimer’s Disease: Where Intracellular and Extracellular Meet
por: van Weering, Jan R. T., et al.
Publicado: (2019)

Where are we coming from? What are we? Where are we going?
por: Ellis, John R.
Publicado: (1995)

Where are we going?
por: Pawl, Ronald P.
Publicado: (2010)

DRUG CONTROL OF HYPERTENSION IN PRIMARY HEALTH CARE CENTERS-REGISTERED PATIENTS, AL-KHOBAR, SAUDI ARABIA
por: Elzubier, Ahmed G., et al.
Publicado: (1997)

The Clusmy Child: Where Are We and Where Are We Going?
por: Hadders-Algra, Mijna, et al.
Publicado: (2003)

European HEPnet: where we are and where we are going
por: Carpenter, B E, et al.
Publicado: (1990)

Iron health: where are we and where are we going?
por: Gotardo, Glória Ines Beal
Publicado: (2011)

Hip Arthroscopy: Where We Are, and Where We Are Going
por: Park, Myung Sik, et al.
Publicado: (2015)

Bioactive Glasses: Where Are We and Where Are We Going?
por: Baino, Francesco, et al.
Publicado: (2018)

Diabetic cardiomyopathy: where we are and where we are going
por: Lee, Wang-Soo, et al.
Publicado: (2017)

Obstetric ultrasound: where are we and where are we going?
por: Abramowicz, Jacques S
Publicado: (2021)

Hidradenitis Suppurativa: Where We Are and Where We Are Going
por: Scala, Emanuele, et al.
Publicado: (2021)

Where We Are and Where We Are Going in Nut Research
por: Salas-Salvadó, Jordi, et al.
Publicado: (2023)

COVID-19: Where We Are and Where We Are Going
por: Abenavoli, Ludovico, et al.
Publicado: (2023)

Telemedicine in ophthalmology - where are we and where are we going?
por: Pîrvulescu, Ruxandra
Publicado: (2023)

Drugs for improving esophageal mucosa defense: where are we now and where are we going?
por: Savarino, Edoardo, et al.
Publicado: (2017)

Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
por: Bonella, Francesco, et al.
Publicado: (2023)

MicroRNA: Potential Targets for the Development of Novel Drugs?
por: Wu, Wei
Publicado: (2012)

CUREs in biochemistry—where we are and where we should go
por: Bell, Jessica K., et al.
Publicado: (2016)

The who, what, where, how, and why of endoscopic submucosal dissection in Canada: A survey among Canadian endoscopists
por: Rai, Mandip, et al.
Publicado: (2021)

DRUG-SUSCEPTIBILITY PATTERN OF MYCOBACTERIUM TUBERCULOSIS AMONG PULMONARY TUBERCULOSIS PATIENTS IN RIYADH, SAUDI ARABIA
por: Al-Awaidy, Salah T., et al.
Publicado: (1997)

Application of Machine Learning in Pulmonary Function Assessment Where Are We Now and Where Are We Going?
por: Giri, Paresh C., et al.
Publicado: (2021)

Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going
por: Coppola, Alessandro, et al.
Publicado: (2023)

Male contraception: where are we going and where have we been?
por: Reynolds-Wright, John Joseph, et al.
Publicado: (2019)

The living universe: where are we? who are we? where are we going?
por: Elgin, Duane, et al.
Publicado: (2009)

Characteristics of Patients With Pulmonary Arterial Hypertension in a Pulmonary Hypertension Association-Accredited Comprehensive Care Center: A Contrast in Features When Compared With US National Registry Data
por: Ingram, Dominique, et al.
Publicado: (2022)

FKBP Ligands—Where We Are and Where to Go?
por: Kolos, Jürgen M., et al.
Publicado: (2018)

Anticipation in Lynch Syndrome: Where We Are Where We Go
por: Bozzao, Cristina, et al.
Publicado: (2011)

Free software at CERN: where are we, where are we going?
por: Fluckiger, Francois, et al.
Publicado: (2013)

Molecular targeted agents—where we are and where we are going
por: Yan, Li
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_hlu2rmqpkm6tj8u4vro4btdnmn